Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
5
Neutral
6
Bullish
3
Bearish
27
Neutral
6
Bullish
13
Bearish
22
Neutral
0
Bullish
10
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Standard Engineering Technology Limited (formerly Standard Glass Lining Technology Limited) is an India‑based specialised engineering and equipment manufacturer providing end-to-end process equipment, turnkey plants, and lifecycle services across pharmaceuticals, chemicals, food & beverages, biotech, power, refinery, petrochemical, nuclear and defence sectors, with capabilities in glass-lined, stainless steel and high‑alloy equipment and expanded engineering services after recent acquisitions.
The company reported robust 9MFY26 revenue of ₹562.2 crore, up 23.6% YoY, and Q3FY26 revenue of ₹195.9 crore up 37.1% YoY, while maintaining an EBITDA margin around 18% despite a QoQ margin dip attributed by management to export timing, higher hiring and project consumables, reflecting disciplined execution and improving working capital collection trends for Standard Engineering Technology Limited.
A deliberate strategic transformation is underway: two material acquisitions (Scigenics and 51% of C2C Engineering) plus global partnerships (AGI/GL Hakko, IPP, Biocon) have repositioned the company from a glass‑lining specialist to an integrated engineering and bioprocess systems platform offering concept-to-commissioning solutions under the Standard Engineering Technology Limited umbrella.
Product and market expansion is tangible—launch of glass-lined shell & tube heat exchangers (200 units booked, 100 delivered), planned commercial launch of conductivity glass-lined reactors in April 2027, and an export target ramp to ~13% in FY26 with guidance toward 15–20% over the medium term, indicating both product differentiation and an explicit export growth agenda for Standard Engineering Technology Limited.
Capital Goods-Non Electrical Equipment
Engineering - Heavy - Glass-lined Equipment
2,464 Cr
High Risk
32.4
34.4
1.5
3.3
203.40
110.70
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
840.00 | 3,175 Cr | 24.62 | 3.38 | 0.18 | 13.61 | 14.16 | 5.94 | |
500.00 | 2,631 Cr | 27.25 | 3.95 | 0.36 | 14.91 | 19.58 | 10.93 | |
123.85 | 2,464 Cr | 32.76 | 3.29 | 0.00 | 9.51 | 12.67 | 6.80 | |
4790.00 | 2,359 Cr | 229.30 | 11.22 | 0.00 | 9.69 | 11.58 | 1.50 | |
361.30 | 2,273 Cr | 41.78 | 5.14 | 0.55 | 17.46 | 19.31 | 7.07 | |
316.00 | 2,192 Cr | 33.96 | 4.32 | 0.34 | 10.96 | 14.15 | 4.81 | |
245.10 | 2,153 Cr | -177.71 | 2.68 | 0.00 | 0.38 | 2.50 | -1.41 |
Standard Engineering Technology Ltd (SETL) is currently trading at 122.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Standard Engineering Technology Limited (formerly Standard Glass Lining Technology Limited) is an India‑based specialised engineering and equipment manufacturer providing end-to-end process equipment, turnkey plants, and lifecycle services across pharmaceuticals, chemicals, food & beverages, biotech, power, refinery, petrochemical, nuclear and defence sectors, with capabilities in glass-lined, stainless steel and high‑alloy equipment and expanded engineering services after recent acquisitions. The company reported robust 9MFY26 revenue of ₹562.2 crore, up 23.6% YoY, and Q3FY26 revenue of ₹195.9 crore up 37.1% YoY, while maintaining an EBITDA margin around 18% despite a QoQ margin dip attributed by management to export timing, higher hiring and project consumables, reflecting disciplined execution and improving working capital collection trends for Standard Engineering Technology Limited. A deliberate strategic transformation is underway: two material acquisitions (Scigenics and 51% of C2C Engineering) plus global partnerships (AGI/GL Hakko, IPP, Biocon) have repositioned the company from a glass‑lining specialist to an integrated engineering and bioprocess systems platform offering concept-to-commissioning solutions under the Standard Engineering Technology Limited umbrella. Product and market expansion is tangible—launch of glass-lined shell & tube heat exchangers (200 units booked, 100 delivered), planned commercial launch of conductivity glass-lined reactors in April 2027, and an export target ramp to ~13% in FY26 with guidance toward 15–20% over the medium term, indicating both product differentiation and an explicit export growth agenda for Standard Engineering Technology Limited.
Over the past 52 weeks, Standard Engineering Technology Ltd has traded between a low of ₹110.70 and a high of ₹203.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Standard Engineering Technology Ltd has a market capitalization of approximately 2,463.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Standard Engineering Technology Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.41 and operates in the Capital Goods-Non Electrical Equipment sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,463.72 Cr, Standard Engineering Technology Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Standard Engineering Technology Ltd operates in the Capital Goods-Non Electrical Equipment sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Standard Engineering Technology Ltd is 32.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Distribution Agreement
Standard Engineering Technology signed a target‑based conditional distribution agreement with API Pharma Pharmaceutical Trading L.L.C (Ajman, UAE) to expand exports across pharma, biopharma and F&B; initial 3‑yr period, extendable to 10 yrs subject to targets with commercial protections.
Distribution Agreement
Standard Engineering Technology signed a target-based conditional distribution agreement with API Pharma Pharmaceutical Trading L.L.C on Mar 5, 2026 to expand exports to the Middle East (initial 3‑year performance period, extendable up to 10 years) across pharmaceuticals, biopharma, food & beverages and related industries, with performance milestones, commercial protections and periodic reviews.
